A third US approval for checkpoint blocker Libtayo (cemiplimab-rwlc) has been won by Regeneron Pharmaceuticals (Nasdaq: REGN) and its partner, French pharma major Sanofi (Euronext: SAN).
The US regulator granted the approval for the first-line treatment of certain people with advanced non-small cell lung cancer (NSCLC), as defined by a genetic test.
In a crowded field led by Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab), Libtayo has thus far failed to make significant progress against other immunotherapy options.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze